Randomized clinical trial of Ligasure™ versus conventional surgery for extended gastric cancer resection

W. J. Lee, T. C. Chen, I. R. Lai, W. Wang, M. T. Huang

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

Background: The Ligasure™ Vessel Sealing System is a haemostatic device designed primarily for use in abdominal surgery. Randomized trials have demonstrated that it is safe and quick for haemorrhoidectomy, but there is no evidence that it confers any advantage in complicated gastrointestinal surgery. The aim of the present study was to examine the value of the Ligasure™ system in extended lymph node dissection (D2) during gastrectomy for cancer in a randomized clinical trial. Methods: D2 gastric resection performed with the Ligasure™ system was compared with resection using conventional haemostatic methods in a prospective randomized trial. Central randomization (40 patients in each group) was performed after a staging laparotomy. The main outcome measures were operating time, intraoperative blood loss, postoperative course and complications. Results: Ligasure™ was associated with less intraoperative blood loss (mean(s.d.) 142(73) versus 239(124) ml; P = 0.001) and a shorter operating time (mean(s.d.) 169(25) versus 222(28) min; P = 0.001) than conventional operation. Postoperative drainage fluid volumes were greater in the Ligasure™ group (mean(s.d.) 1577(940) versus 886(542) ml; P = 0.020). There were no differences in postoperative complications or hospital stay. Conclusion: The Ligasure™ Vessel Sealing System is safe for use in extended lymph node dissection for gastric cancer, and is associated with a shorter operating time and decreased blood loss compared with conventional haemostatic techniques.

Original languageEnglish
Pages (from-to)1493-1496
Number of pages4
JournalBritish Journal of Surgery
Volume90
Issue number12
DOIs
Publication statusPublished - Dec 2003
Externally publishedYes

Fingerprint

Stomach Neoplasms
Randomized Controlled Trials
Hemostatics
Lymph Node Excision
Hemostatic Techniques
Hemorrhoidectomy
Gastrectomy
Random Allocation
Laparotomy
Drainage
Length of Stay
Stomach
Outcome Assessment (Health Care)
Equipment and Supplies
Neoplasms

ASJC Scopus subject areas

  • Surgery

Cite this

Randomized clinical trial of Ligasure™ versus conventional surgery for extended gastric cancer resection. / Lee, W. J.; Chen, T. C.; Lai, I. R.; Wang, W.; Huang, M. T.

In: British Journal of Surgery, Vol. 90, No. 12, 12.2003, p. 1493-1496.

Research output: Contribution to journalArticle

@article{39c657a61e8b459981b76eb90298b273,
title = "Randomized clinical trial of Ligasure™ versus conventional surgery for extended gastric cancer resection",
abstract = "Background: The Ligasure™ Vessel Sealing System is a haemostatic device designed primarily for use in abdominal surgery. Randomized trials have demonstrated that it is safe and quick for haemorrhoidectomy, but there is no evidence that it confers any advantage in complicated gastrointestinal surgery. The aim of the present study was to examine the value of the Ligasure™ system in extended lymph node dissection (D2) during gastrectomy for cancer in a randomized clinical trial. Methods: D2 gastric resection performed with the Ligasure™ system was compared with resection using conventional haemostatic methods in a prospective randomized trial. Central randomization (40 patients in each group) was performed after a staging laparotomy. The main outcome measures were operating time, intraoperative blood loss, postoperative course and complications. Results: Ligasure™ was associated with less intraoperative blood loss (mean(s.d.) 142(73) versus 239(124) ml; P = 0.001) and a shorter operating time (mean(s.d.) 169(25) versus 222(28) min; P = 0.001) than conventional operation. Postoperative drainage fluid volumes were greater in the Ligasure™ group (mean(s.d.) 1577(940) versus 886(542) ml; P = 0.020). There were no differences in postoperative complications or hospital stay. Conclusion: The Ligasure™ Vessel Sealing System is safe for use in extended lymph node dissection for gastric cancer, and is associated with a shorter operating time and decreased blood loss compared with conventional haemostatic techniques.",
author = "Lee, {W. J.} and Chen, {T. C.} and Lai, {I. R.} and W. Wang and Huang, {M. T.}",
year = "2003",
month = "12",
doi = "10.1002/bjs.4362",
language = "English",
volume = "90",
pages = "1493--1496",
journal = "British Journal of Surgery",
issn = "0007-1323",
publisher = "John Wiley and Sons Ltd",
number = "12",

}

TY - JOUR

T1 - Randomized clinical trial of Ligasure™ versus conventional surgery for extended gastric cancer resection

AU - Lee, W. J.

AU - Chen, T. C.

AU - Lai, I. R.

AU - Wang, W.

AU - Huang, M. T.

PY - 2003/12

Y1 - 2003/12

N2 - Background: The Ligasure™ Vessel Sealing System is a haemostatic device designed primarily for use in abdominal surgery. Randomized trials have demonstrated that it is safe and quick for haemorrhoidectomy, but there is no evidence that it confers any advantage in complicated gastrointestinal surgery. The aim of the present study was to examine the value of the Ligasure™ system in extended lymph node dissection (D2) during gastrectomy for cancer in a randomized clinical trial. Methods: D2 gastric resection performed with the Ligasure™ system was compared with resection using conventional haemostatic methods in a prospective randomized trial. Central randomization (40 patients in each group) was performed after a staging laparotomy. The main outcome measures were operating time, intraoperative blood loss, postoperative course and complications. Results: Ligasure™ was associated with less intraoperative blood loss (mean(s.d.) 142(73) versus 239(124) ml; P = 0.001) and a shorter operating time (mean(s.d.) 169(25) versus 222(28) min; P = 0.001) than conventional operation. Postoperative drainage fluid volumes were greater in the Ligasure™ group (mean(s.d.) 1577(940) versus 886(542) ml; P = 0.020). There were no differences in postoperative complications or hospital stay. Conclusion: The Ligasure™ Vessel Sealing System is safe for use in extended lymph node dissection for gastric cancer, and is associated with a shorter operating time and decreased blood loss compared with conventional haemostatic techniques.

AB - Background: The Ligasure™ Vessel Sealing System is a haemostatic device designed primarily for use in abdominal surgery. Randomized trials have demonstrated that it is safe and quick for haemorrhoidectomy, but there is no evidence that it confers any advantage in complicated gastrointestinal surgery. The aim of the present study was to examine the value of the Ligasure™ system in extended lymph node dissection (D2) during gastrectomy for cancer in a randomized clinical trial. Methods: D2 gastric resection performed with the Ligasure™ system was compared with resection using conventional haemostatic methods in a prospective randomized trial. Central randomization (40 patients in each group) was performed after a staging laparotomy. The main outcome measures were operating time, intraoperative blood loss, postoperative course and complications. Results: Ligasure™ was associated with less intraoperative blood loss (mean(s.d.) 142(73) versus 239(124) ml; P = 0.001) and a shorter operating time (mean(s.d.) 169(25) versus 222(28) min; P = 0.001) than conventional operation. Postoperative drainage fluid volumes were greater in the Ligasure™ group (mean(s.d.) 1577(940) versus 886(542) ml; P = 0.020). There were no differences in postoperative complications or hospital stay. Conclusion: The Ligasure™ Vessel Sealing System is safe for use in extended lymph node dissection for gastric cancer, and is associated with a shorter operating time and decreased blood loss compared with conventional haemostatic techniques.

UR - http://www.scopus.com/inward/record.url?scp=0348041950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0348041950&partnerID=8YFLogxK

U2 - 10.1002/bjs.4362

DO - 10.1002/bjs.4362

M3 - Article

VL - 90

SP - 1493

EP - 1496

JO - British Journal of Surgery

JF - British Journal of Surgery

SN - 0007-1323

IS - 12

ER -